Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eledoisin is a naturally occurring undecapeptide (11 amino acids) neuropeptide of the tachykinin family, originally isolated from the posterior salivary glands of Mediterranean octopuses (*Eledone moschata* and *E. aldovandi*)[4][8]. It acts as a potent agonist at neurokinin receptors, especially NK1 and NK2, mediating smooth muscle contraction and sensory neurotransmission[1][4]. Eledoisin exhibits pharmacological activities such as vasodilation, increased capillary permeability, stimulation of extravascular smooth muscle contraction, and modulation of ion transport in certain tissues[4][6][8]. Its sequence is pGlu-Pro‑Ser‑Lys‑Asp‑Ala‑Phe‑Ile‑Gly‑Leu‑Met-NH2. While it has been widely used in research to study tachykinins and their receptors due to its availability before mammalian tachykinins were characterized, it is not approved for clinical use in humans[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eledoisin.